File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

TitleLong-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
Authors
Issue Date2010
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 2010, v. 52 n. 3, p. 886-893 How to Cite?
AbstractOne year of treatment with entecavir (0.5 mg daily) in nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) resulted in significantly improved liver histology and virological and biochemical endpoints in comparison with lamivudine. Patients who received at least 3 years of cumulative entecavir therapy in phase 3 studies and a long-term rollover study and underwent long-term liver biopsy were evaluated for improvements in histological appearance. Sixty-nine patients [50 HBeAg-positive and 19 HBeAg-negative] receiving entecavir therapy underwent long-term liver biopsy (median time of biopsy = 6 years, range = 3-7 years). Histological improvement was analyzed for 57 patients who had adequate baseline biopsy samples, baseline Knodell necroinflammatory scores ≥2, and adequate long-term biopsy samples. At the time of long-term biopsy, all patients in the cohort had a hepatitis B virus DNA level <300 copies/mL, and 86% had a normalized alanine aminotransferase level. Histological improvement (≥2-point decrease in the Knodell necroinflammatory score and no worsening of the Knodell fibrosis score) was observed in 96% of patients, and a ≥1-point improvement in the Ishak fibrosis score was found in 88% of patients, including all 10 patients with advanced fibrosis or cirrhosis at the phase 3 baseline. Conclusion: The majority of nucleoside-naive patients with CHB who were treated with entecavir in this long-term cohort achieved substantial histological improvement and regression of fibrosis or cirrhosis. Copyright © 2010 by the American Association for the Study of Liver Diseases.
Persistent Identifierhttp://hdl.handle.net/10722/163334
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChang, TTen_US
dc.contributor.authorLiaw, YFen_US
dc.contributor.authorWu, SSen_US
dc.contributor.authorSchiff, Een_US
dc.contributor.authorHan, KHen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorSafadi, Ren_US
dc.contributor.authorLee, SSen_US
dc.contributor.authorHalota, Wen_US
dc.contributor.authorGoodman, Zen_US
dc.contributor.authorChi, YCen_US
dc.contributor.authorZhang, Hen_US
dc.contributor.authorHindes, Ren_US
dc.contributor.authorIloeje, Uen_US
dc.contributor.authorBeebe, Sen_US
dc.contributor.authorKreter, Ben_US
dc.date.accessioned2012-09-05T05:30:11Z-
dc.date.available2012-09-05T05:30:11Z-
dc.date.issued2010en_US
dc.identifier.citationHepatology, 2010, v. 52 n. 3, p. 886-893en_US
dc.identifier.issn0270-9139en_US
dc.identifier.urihttp://hdl.handle.net/10722/163334-
dc.description.abstractOne year of treatment with entecavir (0.5 mg daily) in nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) resulted in significantly improved liver histology and virological and biochemical endpoints in comparison with lamivudine. Patients who received at least 3 years of cumulative entecavir therapy in phase 3 studies and a long-term rollover study and underwent long-term liver biopsy were evaluated for improvements in histological appearance. Sixty-nine patients [50 HBeAg-positive and 19 HBeAg-negative] receiving entecavir therapy underwent long-term liver biopsy (median time of biopsy = 6 years, range = 3-7 years). Histological improvement was analyzed for 57 patients who had adequate baseline biopsy samples, baseline Knodell necroinflammatory scores ≥2, and adequate long-term biopsy samples. At the time of long-term biopsy, all patients in the cohort had a hepatitis B virus DNA level <300 copies/mL, and 86% had a normalized alanine aminotransferase level. Histological improvement (≥2-point decrease in the Knodell necroinflammatory score and no worsening of the Knodell fibrosis score) was observed in 96% of patients, and a ≥1-point improvement in the Ishak fibrosis score was found in 88% of patients, including all 10 patients with advanced fibrosis or cirrhosis at the phase 3 baseline. Conclusion: The majority of nucleoside-naive patients with CHB who were treated with entecavir in this long-term cohort achieved substantial histological improvement and regression of fibrosis or cirrhosis. Copyright © 2010 by the American Association for the Study of Liver Diseases.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_US
dc.relation.ispartofHepatologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAntiviral Agents - Pharmacology - Therapeutic Useen_US
dc.subject.meshBiopsyen_US
dc.subject.meshCohort Studiesen_US
dc.subject.meshDna, Viral - Metabolismen_US
dc.subject.meshFemaleen_US
dc.subject.meshGuanine - Analogs & Derivatives - Pharmacology - Therapeutic Useen_US
dc.subject.meshHepatitis B Virus - Geneticsen_US
dc.subject.meshHepatitis B, Chronic - Drug Therapy - Pathologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLiver - Drug Effects - Pathology - Virologyen_US
dc.subject.meshLiver Cirrhosis - Drug Therapy - Pathologyen_US
dc.subject.meshLongitudinal Studiesen_US
dc.subject.meshMaleen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSeverity Of Illness Indexen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleLong-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis Ben_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/hep.23785en_US
dc.identifier.pmid20683932-
dc.identifier.scopuseid_2-s2.0-77956639159en_US
dc.identifier.hkuros181147-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77956639159&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume52en_US
dc.identifier.issue3en_US
dc.identifier.spage886en_US
dc.identifier.epage893en_US
dc.identifier.isiWOS:000281423000011-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridChang, TT=7404725147en_US
dc.identifier.scopusauthoridLiaw, YF=35310933100en_US
dc.identifier.scopusauthoridWu, SS=8836202200en_US
dc.identifier.scopusauthoridSchiff, E=7102846957en_US
dc.identifier.scopusauthoridHan, KH=7402963689en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridSafadi, R=7005020162en_US
dc.identifier.scopusauthoridLee, SS=35798391900en_US
dc.identifier.scopusauthoridHalota, W=7003967450en_US
dc.identifier.scopusauthoridGoodman, Z=35418729400en_US
dc.identifier.scopusauthoridChi, YC=7103206598en_US
dc.identifier.scopusauthoridZhang, H=36571190900en_US
dc.identifier.scopusauthoridHindes, R=36570150600en_US
dc.identifier.scopusauthoridIloeje, U=6602353135en_US
dc.identifier.scopusauthoridBeebe, S=36570055600en_US
dc.identifier.scopusauthoridKreter, B=6603129787en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats